Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Feature|Articles|September 11, 2023
- Pharmaceutical Executive: September 2023
- Volume 43
- Issue 9
Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Advertisement
Follow the links below to read about each product:
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Articles in this issue
about 3 years ago
Pharmaceutical Executive, September 2023 Issue (PDF)about 3 years ago
A New Era of Ethical Leadershipabout 3 years ago
Survival Story: Enhertuabout 3 years ago
Gut Instinct: Rebyotaabout 3 years ago
Delaying Disease Onset: Tzieldabout 3 years ago
New Beginnings: Sunlencaabout 3 years ago
A Heartfelt Solution: Camzyosabout 3 years ago
Fortifying Defenses Pre-Patent Cliffabout 3 years ago
New Product Planning: The Function's Evolution in Pharmaabout 3 years ago
No Rate Relief in Sight for BiotechAdvertisement
Related to this article
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
3
Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham
4
Pharmaceutical Executive Daily: FDA Approves Fayuvi
5